ESTRO 2024 - Abstract Book

S2511

Clinical - Urology

ESTRO 2024

(53,2%) with choline tracer. All patients had transperineal fusional prostate mapping biopsy from August 2021 to August 2023. One patient had it twice.

Results:

The median samples per prostate were 22 (range 19-27). The local recurrences were detected in 40 (85%) biopsies. The recurrence was suspected in 34 MRs and was confirmed with biopsy in 29 (85%) cases, but in 12 (35%) cases, the disease was outside the DIL. MR had a sensitivity 80,5% but a specificity 37,5%. With PET-PSMA, the recurrence was suspected in 17 (90%) cases but confirmed in 13 (76%) patients and in 5 cases (38%) outside DIL (sensitivity 93,7%, specificity 20%). With PET-choline, the recurrence was suspected in 19 (76%) cases but confirmed in 17 (89%) with 100% in DIL (sensitivity 77,2%, specificity 0%). However, combining the PET-PSMA and MR predicts the recurrence with a sensitivity of 75% and specificity of 80%.

Conclusion:

Combining PET-PSMA and MR has the highest sensitivity and specificity in the diagnosis of local recurrence of prostate cancer after RT in our study. However, omitting the biopsy before salvage treatment is still questionable. Moreover, the mapping biopsy still seems necessary for focal salvage treatment.

Keywords: prostate cancer recurence, biopsy, imaging

2341

Digital Poster

Prostate Cancer ultra-hypofractionation: single-center early tolerance analysis

Giuseppe Carlo Iorio 1 , Ilaria Bonavero 1 , Sara Bartoncini 1 , Elena Gallio 2 , Diego Bongiovanni 1 , Sara Gaspari 1 , Valeria Chiofalo 1 , Cristiano Grossi 1 , Fabio Menegatti 1 , Edoardo Gozzelino 1 , Erica Maria Cuffini 1 , Giuliana Petruzzellis 1 , Marzia Cerrato 1 , Bruna Lo Zito 1 , Chiara Casale 1 , Francesca Catena 1 , Eulalie Joelle Tondji Ngassam 1 , Mario Levis 1 , Ramona Parise 1 , Umberto Ricardi 1 1 University of Turin, Department of Oncology, Turin, Italy. 2 University of Turin, Department of Medical Physics, Turin, Italy

Purpose/Objective:

Early tolerance evaluation of ultra-hypofractionated RT for localized (low- to high-risk) prostate cancer (PCa).

Material/Methods: